Misset J L, Mathé G, Santelli G, Gouvela J, Homasson J P, Sudre M C, Gaget H
Acta Vitaminol Enzymol. 1985;7 Suppl:21-5.
40 voluntary heavy smokers (over 15 packets-years) were selected for and have completed a six months etretinate treatment on the basis of an index of metaplasia (IM) greater than 15% determined according to the following procedure: bronchoscopy with systematic biopsies in 10 sites of the bronchial tree. Each biopsy was cut into 10 sections and an IM was calculated: (Formula: see text). Etretinate, a retinoid derivative, was given orally at the daily dose of 25 mg, at the end of which they underwent a second fibroscopy protocol. A highly significant reduction of IM (p = 10(-5)) was observed after 6 months of treatment for those of the patients who maintained their smoking habits during treatment. Besides, the 4 patients who stopped smoking while under treatment and are excluded from the statistical analysis, all had a complete regression of metaplasia at the second fibroscopy. No morbidity was due to etretinate or fibroscopy. Etretinate significantly reduces potentially precancerous bronchial epidermoid metaplasia in heavy smokers. Its association with smoking arrest may induce a rapid restoration of bronchial epithelium to normal.
40名自愿的重度吸烟者（吸烟量超过15包年）入选并基于根据以下程序确定的化生指数（IM）大于15%完成了为期6个月的依曲替酯治疗：在支气管树的10个部位进行系统性活检的支气管镜检查。将每个活检标本切成10个切片并计算IM：（公式：见正文）。依曲替酯，一种维甲酸衍生物，以每日25毫克的剂量口服，治疗结束后他们接受第二次纤维镜检查方案。对于在治疗期间保持吸烟习惯的患者，治疗6个月后观察到IM有极显著降低（p = 10⁻⁵）。此外，在治疗期间戒烟且被排除在统计分析之外的4名患者，在第二次纤维镜检查时化生均完全消退。没有发病率是由依曲替酯或纤维镜检查引起的。依曲替酯可显著降低重度吸烟者潜在的癌前支气管表皮化生。它与戒烟相结合可能会促使支气管上皮迅速恢复正常。
